Q-omics provides the consensus-scored YLPM1 profile across patient tissues and cancer cell-line models. YLPM1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, YLPM1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, YLPM1 protein abundance shows 25,784 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where YLPM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YLPM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YLPM1 survival associations across molecular data types. YLPM1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (11) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YLPM1 RNA expression–survival associations across cancer types. High YLPM1 expression shows unfavorable associations in ACC and STAD, but favorable associations in KIRC, BRCA, SCLC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for YLPM1 RNA expression.
This table summarizes YLPM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for YLPM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YLPM1 shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, LIHC, CHOL and STAD. The THCA box plot shows higher YLPM1 RNA expression in normal versus tumor tissue (log2 FC = −0.614, t-test p < 0.001).
This table shows molecular features associated with YLPM1 in patient tissues and cancer cell lines. In patient samples, YLPM1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, YLPM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
